Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Dose, Infection, and Disease Outcomes for Coronavirus Disease 2019 (COVID-19): A Review.

Autor:	Brosseau LM; Center for Infectious Disease Research and Policy, University of Minnesota, Minneapolis, Minnesota, USA., Escandón K; School of Medicine, Universidad del Valle, Cali, Colombia.; Grupo de Investigación en Virus Emergentes y Enfermedad (VIREM), Department of Microbiology, Universidad del Valle, Cali, Colombia., Ulrich AK; Center for Infectious Disease Research and Policy, University of Minnesota, Minneapolis, Minnesota, USA.; Division of Environmental Health Sciences, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA., Rasmussen AL; Vaccine and Infectious Disease Organization, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.; Georgetown Center for Global Health Science and Security, Washington, D.C., USA., Roy CJ; Tulane National Primate Research Center, Division of Microbiology, Covington, Louisiana, USA.; Department of Microbiology and Immunology, Tulane University School of Medicine, New Orleans, Louisiana, USA., Bix GJ; Clinical Neuroscience Research Center, Departments of Neurosurgery and Neurology, Tulane University School of Medicine, New Orleans, Louisiana, USA.; Tulane Brain Institute, Tulane University, New Orleans, Louisiana, USA.; School of Public Health and Tropical Medicine, Tulane University, New Orleans, Louisiana, USAand., Popescu SV; Georgetown Center for Global Health Science and Security, Washington, D.C., USA.; Biodefense Program, Schar School of Policy and Government, George Mason University, Arlington, Virginia, USA., Moore KA; Center for Infectious Disease Research and Policy, University of Minnesota, Minneapolis, Minnesota, USA., Osterholm MT; Center for Infectious Disease Research and Policy, University of Minnesota, Minneapolis, Minnesota, USA.; Division of Environmental Health Sciences, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA.
Jazyk:	angličtina
Zdroj:	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2022 Aug 24; Vol. 75 (1), pp. e1195-e1201.
DOI:	10.1093/cid/ciab903
Abstrakt:	The relationship between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) dose, infection, and coronavirus disease 2019 (COVID-19) outcomes remains poorly understood. This review summarizes the existing literature regarding this issue, identifies gaps in current knowledge, and suggests opportunities for future research. In humans, host characteristics, including age, sex, comorbidities, smoking, and pregnancy, are associated with severe COVID-19. Similarly, in animals, host factors are strong determinants of disease severity, although most animal infection models manifest clinically with mild to moderate respiratory disease. The influence of variants of concern as it relates to infectious dose, consequence of overall pathogenicity, and disease outcome in dose-response remains unknown. Epidemiologic data suggest a dose-response relationship for infection contrasting with limited and inconsistent surrogate-based evidence between dose and disease severity. Recommendations include the design of future infection studies in animal models to investigate inoculating dose on outcomes and the use of better proxies for dose in human epidemiology studies. (© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu